Cilostazol for the Prevention of Recurrent Stroke: Results from CSPS II

March 2010
MD Conference Express;Mar2010, p13
Academic Journal
The article presents a study which proves noninferiority of Cilostazol (CLZ) compared with aspirin to prevent stroke reoccurrence among patients with noncardioembolic cerebral infarction. The study administered CLZ and aspirin among patients with primary endpoint of symptomatic stroke which include the cerebral infarction of the occurance of intracerebral hemorrhage (ICH) during the treatment period. The study evaluates the effect the said drugs on the secondary endpoints, which include the reoccurrence of symptomatic cerebral infarction, the composite of stroke, heart failure, and the myocardial infarction. Results show that about 25.7% qualified risk decline in stroke reoccurrence in patients who are treated with CLZ, and there is a 20.1% risk reduction in the secondary endpoint stoke.


Related Articles

  • Thrombolytic therapy does not increase the risk of post-MI stroke.  // Modern Medicine;Sep97, Vol. 65 Issue 9, p55 

    Presents an abstract of the article `Ischemic Cerebral Infarction after rt-PA and Heparin Therapy for Acute Myocardial Infarction: The TIMI-II Pilot and Randomized Clinical Trial Combined Experience,' by M.A. Sloan, T.R. Price et al published in the June 1997 issue of `Stroke' journal.

  • Latest Research.  // Medical Economics;11/17/2006, Vol. 83 Issue 22, p10 

    The article features several medical research articles. The featured articles include the research on inhaled insulin as alternative pre-meal insulin administration to shots. Also included are the research on treating severe heart failure through a left ventricular assist device and the research...

  • Drug Treatment of Elderly Patients with Acute Myocardial Infarction: Practical Recommendations. Aronow, W.S. // Drugs & Aging;2001, Vol. 18 Issue 11, p807 

    Aspirin (acetylsalicylic acid) should be administered to patients on day 1 of an acute myocardial infarction (MI) and continued indefinitely. Early intravenous β-blockade should be used during acute MI. β-blockers should be continued indefinitely. Angiotensin-converting enzyme (ACE)...

  • Aspirin for Everyone? Wilke, Allan J. // Internal Medicine Alert;3/15/2012, Vol. 34 Issue 5, p33 

    Aspirin can reduce the risk of nonfatal myocardial infarction, but not mortality, in people without coronary vascular disease, at the expense of increased risk of bleeding. It should not be routinely recommended.

  • First aldosterone-blocker approved for CHF.  // Drug Topics;10/20/2003, Vol. 147 Issue 20, p8 

    Focuses on the U.S. Food and Drug Administration's approval of an aldosterone-blocker for the congestive heart failure patients following an acute myocardial infarction.

  • COMMENTARY. Prabhakar, Manu; Massel, David // Evidence Based Medicine;Sep2003, p146 

    The author reflects on the advantage of using adjunctive treatment with eplerenone for patients with congestive heart failure (CHF) and acute myocardial infarction (MI).

  • Evidence-based co-medication in heart failure: necessary or bystander? Verheugt, Freek W. A. // European Journal of Heart Failure;Jan2014, Vol. 16 Issue 1, p1 

    No abstract available.

  • Instructions for living.  // Men's Health;Nov96, Vol. 11 Issue 9, p138 

    Announces that the US Food and Drug Administration is now allowing physicians to recommend that patients use aspirin during suspected heart attacks.

  • Eye on the Literature.  // Formulary;Dec2002, Vol. 37 Issue 12, p624 

    Outlines research on drugs from various publications compiled as of December 2002. Impact of ramipril on outcome of patients with myocardial infarction; Sex-based differences in the effect of digoxin for treatment of heart failure; Aspirin therapy after bypass surgery.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics